Table 2.
Pathological Characteristics Prostatectomy (Number of Patients) |
Number of Patients (%) | Serum PSA | PCA3 Score | T2 Score | PHI | ||||
---|---|---|---|---|---|---|---|---|---|
Median (IQR) | p Value | Median (IQR) | p Value | Median (IQR) | p Value | Median (IQR) | p Value | ||
Pathological T stage n = 154 |
pT2 n = 106 (69%) |
6.5 (5.0–9.0) |
0.467 | 47 (23–82) |
0.724 | 27 (5–106) |
0.027 | 41 (32–53) |
0.086 |
≥pT3 n = 48 (31%) |
6.4 (5.2–10.9) |
40 (25–111) |
52 (10–352) |
47 (34–59) |
|||||
Gleason stage n = 154 |
G6 n = 22 (14%) |
6.5 (4.6–11.0) |
0.739 | 47 (23–81) |
0.897 | 38 (6–148) |
0.123 | 34 (31–40) |
0.013 |
G ≥ 7 n = 132 (86%) |
6.5 (5.2–9.3) |
43 (23–90) |
35 (7–151) |
44 (34–57) |
|||||
Total tumor volume (mL) a
n = 153 |
<0.5 n = 19 (12%) |
6.2 (4.1–10.1) |
0.276 | 23 (15–47) |
0.004 | 14 (1–105) |
0.090 | 32 (27–42) |
0.002 |
≥0.5 n = 134 (88%) |
6.5 (5.1–9.3) |
48 (25–94) |
37 (6–154) |
44 (34–57) |
|||||
Number of tumor foci n = 154 |
Uni n = 41 (27%) |
6.1 (4.3–11.0) |
0.230 | 27 (19–49) |
0.002 | 55 (8–178) |
0.299 | 41 (33–52) |
0.410 |
Multi n = 113 (73%) |
6.6 (5.4–9.2) |
51 (27–94) |
33 (3–127) |
43 (33–57) |
|||||
Blood embols n = 154 |
No n = 148 (96%) |
6.5 (5.0–9.1) |
0.030 | 44 (23–85) |
0.253 | 35 (5–138) |
0.709 | 42 (33–55) |
0.009 |
Yes n = 6 (4%) |
12.9 (8.6–18.1) |
103 (25–148) |
20 (2–164) |
79 (46–140) |
|||||
Positive resection margins n = 154 |
R0 n = 121 (79%) |
6.3 (5.0–8.8) |
0.029 | 42 (23–82) |
0.241 | 36 (5–137) |
0.620 | 40 (32–53) |
0.007 |
R1 n = 33 (21%) |
7.8 (5.9–14.1) |
61 (26–110) |
29 (3–214) |
50 (41–65) |
Abbreviations: IQR: interquartile range; PCA3: prostate cancer gene 3; PHI: Prostate Health Index; PSA: prostate-specific antigen; T2: TMPRSS2:ERG fusion gene; a: median total tumor volume = 2.2 (IQR: 0.9–4.1).